

# Risk Factors of Preterm Birth in Women After Local Treatment of Cervical Intraepithelial Neoplasia – a Retrospective Cohort Study

## Risikofaktoren für eine Frühgeburt bei Frauen nach lokaler Behandlung einer zervikalen intraepithelialen Neoplasie – eine retrospektive Kohortenstudie



### Authors

Johannes Stubert<sup>1</sup> , Elisa Stratmann<sup>1</sup>, Bernd Gerber<sup>1</sup>, Ellen Mann<sup>1</sup>

### Affiliations

1 Department of Obstetrics and Gynecology, Rostock University Medical Center, Rostock, Germany

### Key words

cervical dysplasia, LLETZ, laser vaporization, conization, preterm birth, risk assessment

### Schlüsselwörter

zervikale Dysplasie, LLETZ, Laservaporisation, Konisation, Frühgeburt, Risikoabwägung

received 16.5.2022

accepted after revision 25.7.2022

published online 8.11.2022

### Bibliography

Geburtsh Frauenheilk 2022; 82: 1397–1405

DOI 10.1055/a-1909-0735

ISSN 0016-5751


© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

### Correspondence

Johannes Stubert, PhD, MD  
Department of Obstetrics and Gynecology  
Rostock University Medical Center  
Suedring 81  
18059 Rostock, Germany  
[johannes.stubert@uni-rostock.de](mailto:johannes.stubert@uni-rostock.de)

 Additional material is available at <https://doi.org/10.1055/a-1909-0735>.

### ABSTRACT

**Purpose** A previous cervical intraepithelial neoplasia is associated with an increased obstetrical risk. It was the aim of the study to identify risk factors of preterm birth in patients with cervical intraepithelial neoplasia in dependence of the treatment modality (excisional vs. ablative).

**Methods** Women with treated cervical intraepithelial neoplasia and subsequent pregnancy (n = 155) were included in this retrospective study. Methods of treatment were either conization by large loop excision of the transformation zone (LLETZ) or ablative laser vaporization.

**Results** Of the total population 60.6% (n = 94) had a conization and 39.4% (n = 61) a laser vaporization alone. The frequency of preterm birth < 37 weeks was 9.7% (n = 15) without differences between conization and laser (11.7 vs. 6.7%, p = 0.407) with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 0.6–6.2). Preterm birth < 34 weeks was found in 2.6% (n = 4), of which all had a conization (4.3 vs. 0%, p = 0.157). Risk factors for preterm birth were repeated cervical intervention (OR 4.7 [95% CI 1.5–14.3]), especially a combination of conization and laser ablation (OR 14.9 [95% CI 4.0–55.6]), age at intervention < 30 years (OR 6.0 [95% CI 1.3–27.4]), a history of preterm birth (OR 4.7 [95% CI 1.3–17.6]) and age at delivery < 28 years (OR 4.7 [95% CI 1.5–14.3]).

**Conclusion** The large loop excision of the transformation zone as a modern, less invasive ablative treatment did not obviously increase the risk of preterm birth compared to laser vaporization. The most important risk factor for preterm delivery was the need of a repeated intervention, especially at younger age. We assume that the persistence or recurrence of the cervical intraepithelial neoplasia following a high-risk human papillomavirus infection is mainly responsible for the observed effect.

## ZUSAMMENFASSUNG

**Zielsetzung** Eine frühere intraepitheliale Neoplasie der Zervix wird mit einem höheren geburtshilflichen Risiko assoziiert. Ziel dieser Studie war es, die Risikofaktoren für eine Frühgeburt bei Patientinnen mit einer zervikalen intraepithelialen Neoplasie in der Anamnese zu identifizieren in Abhängigkeit von der Behandlungsmodalität (Exzision vs. ablativ Behandlung).

**Methoden** In dieser retrospektiven Studie wurden Frauen aufgenommen, die zuvor wegen einer zervikalen intraepithelialen Neoplasie behandelt worden waren und danach schwanger wurden ( $n = 155$ ). Die Behandlungsmethode bestand entweder aus Konisation mittels Schlingenexzision der Transformationszone (LLETZ) oder ablativer Laservaporisation.

**Ergebnisse** Von der Gesamtkohorte erhielten 60,6% ( $n = 94$ ) eine Konisation und 39,4% ( $n = 61$ ) eine Laservaporisation. Die Frequenz der Frühgeburten vor der 37. Schwangerschaftswoche betrug 9,7% ( $n = 15$ ). Es gab keinen Unterschied zwischen Konisation und Laserbehandlung (11,7 vs. 6,7%,  $p = 0,407$ ) mit einer Odds Ratio (OR) von 1,9 (95%-Konfidenzintervall [KI] 0,6–6,2). Eine Frühgeburt vor der 34. Schwanger-

schaftswoche trat bei 2,6% ( $n = 4$ ) auf, und alle Betroffenen hatten zuvor eine Konisation erhalten (4,3 vs. 0%,  $p = 0,157$ ). Risikofaktoren für eine Frühgeburt waren wiederholte zervikale Prozeduren (OR 4,7 [95%-KI 1,5–14,3]), vor allem eine Kombination aus Konisation und Laserablation (OR 14,9 [95%-KI 4,0–55,6]), Alter beim Eingriff < 30 Jahre (OR 6,0 [95%-KI 1,3–27,4]), Frühgeburt in der Anamnese (OR 4,7 [95%-KI 1,3–17,6]) sowie Alter bei der Entbindung < 28 Jahre (OR 4,7 [95%-KI 1,5–14,3]).

**Schlussfolgerung** Die Schlingenexzision der Transformationszone stellt eine moderne, weniger invasive ablativ Behandlung dar, die offenkundig nicht das Risiko einer Frühgeburt erhöht verglichen mit der Laservaporisation. Der wichtigste Risikofaktor für eine frühgeburtliche Entbindung waren wiederholte Prozeduren zur Behandlung von Neoplasien, vor allem in jüngeren Jahren. Wir nehmen an, dass die Persistenz bzw. das Wiederauftreten einer zervikalen intraepithelialen Neoplasie nach einer Infektion mit einem Hochrisikoform des humanen Papillomavirus maßgeblich verantwortlich für die beobachtete Wirkung ist.

## Abbreviations

|       |  |
|-------|--|
| CI    | confidence interval                        |
| CIN   | cervical intraepithelial neoplasia         |
| HPV   | human papillomavirus                       |
| HSIL  | high-grade squamous intraepithelial lesion |
| LLETZ | large loop excision of transformation zone |
| LV    | laser vaporization                         |
| OR    | odds ratio                                 |
| PTB   | preterm birth                              |

## Introduction

The treatment of the cervical intraepithelial neoplasia (CIN) by conization has been widely associated with an increased risk of preterm birth (PTB) [1, 2, 3]. The risk rises with the invasiveness of the intervention and was most obvious after performance of cold knife conization [4]. However, considering less invasive and currently preferred methods of excisional treatment like Large Loop excision of Transformation Zone (LLETZ) or Loop Electrical Excision Procedure (LEEP) the association was only weak or indistinct [4, 5, 6, 7]. This coincides with the observation of a greater risk of PTB with an increasing cone depth [5, 8].

Remarkably, an increased risk of PTB was even observed in women who were treated by minimally invasive laser ablation only and in untreated women with precancerous lesions of the cervix compared to a healthy control group [2]. These results suggest that treatment itself with the removal of tissue is not the only reason for the observed increased obstetric risk. In a recent Cochrane review the observed adverse obstetrics effects were lower if the comparison group consisted of women with CIN without treatment compared to external or internal comparators [3]. In a Swedish population based study, the frequency of PTB was 30%


higher in women with abnormal cervical cytology irrespective of treatment compared to healthy women [9]. Similar results were observed in a retrospective Australian cohort study, in which the diagnosis of a precancerous lesion of the cervix resulted in an increased risk of PTB in both treated and untreated women [7]. Consequently, the comparison of women treated for CIN with unaffected women may overestimate the treatment-related effects on risk of PTB and neglect other co-factors which could contribute to the increase in risk.

Human papillomavirus (HPV) infection during the reproductive age is common and usually resolves within one to two years [10]. However, the persistence of the HPV infection, which is necessary for development of cervical dysplasia, may indicate a risk constellation for PTB by its own. Proofing this hypothesis is difficult, because the avoidance of any therapy in cases of persistent or high grade CIN is not justifiable and therefore a direct comparison of pregnancy outcome between treated and untreated women is not feasible. It was the goal of our study, to identify putative risk factors for PTB in a cohort of pregnant women with a history of CIN necessary for treatment. In this retrospective cohort study, we compared the pregnancy outcome between women after excisional cervical treatment by LLETZ and/or ablativ treatment by Laser vaporization (LV) only.

## Material and Methods

### Recruitment of patients

This retrospective, single center cohort study was conducted on a German tertiary perinatal care center. Using the German coding system for medical procedures and the international classification of diseases (10th revision) we searched for all women with an excisional or ablativ intervention on the cervix and a subsequent



► Fig. 1 Flow diagram of patient selection with criteria of exclusion.

pregnancy between November 2011 and December 2017. Only women with a history of CIN and a subsequent singleton pregnancy to at least 20 completed gestational weeks were included. After exclusion of doublettes and inappropriate cases 155 women were suitable for analysis (► Fig. 1). Pregnancies before cervical interventions were allowed, so that some patients revealed a history of a previous preterm birth or abortion.

### Data collection and definitions

Two treatment modalities for CIN were used: LLETZ as excisional and LV as ablative intervention. An additional colposcopically controlled LV of lower stages of CIN in the periphery of the cervix during the LLETZ procedure in the same session was usual and classified as LLETZ. The LV group comprises only interventions with exclusive use of LV and without LLETZ. In contrast, repeated intervention was defined as at minimum two cervical interventions in different sessions following persistence or recurrence of CIN.

For data analysis, we used the following definitions: CIN 2+ comprises all patients with CIN grade 2 and higher. The results of the hybrid capture II test (HC2, Qiagen, Hilden, Germany) allowed the detection of HPV high risk types.

For the approximation of the cone volume (V) we used the following formula for calculation of a cylindrical volume:  $V = \pi * r^2 * h$ . The radius r corresponds to half of the mean diameter and the height is equal to the depth of the cone. The formula was chosen as the geometry of the thin resection specimen after LLETZ corresponds better to a cylinder than a cone [11].

Gestational age was calculated from the first day of the last menstrual period and was corrected by ultrasound if measurements of the crown-rump-length during the first trimester revealed a difference of seven or more days.

Calculation of birth weight centiles was based on the German perinatal statistic [12]. Perinatal mortality comprises intrauterine demise and neonatal death during the first 28 days after delivery.

### Statistical analysis

All data were stored and analyzed using the IBM SPSS statistical package 25 (SPSS Inc. Chicago, IL, USA), Excel 2013 (Microsoft Corporation, Redmond, WA, USA) and the R 4.1.2 and R-Studio statistical software [13, 14]. Testing for differences in continuous variables between groups was done using Student's t-test or Mann-Whitney U-test as appropriate; comparisons of categorical variables between groups were done with Fisher's exact test. Diag-

nostic odd ratios (OR) with 95% CI were given. All P values were obtained using two-sided statistical tests, and values < 0.05 were considered statistically significant.

A logistic regression model was used to assess the independence of specific risk parameters and to compute a combined risk model for preterm birth. The following risk factors for preterm birth were included: repeated cervical intervention, age below 28 years at delivery, age below 30 years at intervention, preterm birth or late abortion in history. Receiver operating characteristics (ROC) curves and the area under the curve (AUC) were computed using the combined risk models. Based on the model with the best test characteristic we developed a risk prediction score. Therefore, the scoring points were weighted relative to the values of the regression coefficients. For the sum score the ROC-AUC was computed and the optimal cut-off value (minimal distance to sensitivity and specificity of 1) was calculated by using the following equation:  $(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2$ .

The Ethics Committee of the University of Rostock does not request formal approval for anonymized retrospective analysis of clinical data.

## Results

### Patient characteristics

Ninety-four of 155 patients (60.6%) received an excisional treatment by LLETZ, 61 patients (39.4%) were treated by LV alone (► **Table 1**). The majority of patients (81.3%, n = 126) had only one intervention. Of the remaining women 14.2% (n = 22) had two and 4.5% (n = 7) had three cervical interventions. In case of a repeated intervention (18.7%, n = 29) the following types of interventions were performed: repeated LLETZ in 24.1% (n = 7), repeated LV in 34.5% (n = 10) and a subsequent LV after LLETZ in 41.4% (n = 12). There was no case with LLETZ after LV. The patients with repeated LLETZ had a positive margin of the cone in 71.4% (n = 5/7). Women with ablative treatment were more frequently primiparous (63.9% vs. 46.8%, p = 0.048). As expected, occurrence of high-grade squamous intraepithelial lesion (HSIL) was lower in the LV group (74.1% vs. 96.8%, p < 0.001). No patient received a surgical cerclage and in only one patient, a pessary was vaginally inserted, subsequently resulting in a PTB at 29 weeks of gestation. Sufficient data on progesterone application were missing.

► **Table 1** Patient characteristics comparing the groups with excisional treatment and ablative treatment.

|  | All patients     | Excisional treatment (LLETZ) | Ablative treatment (Laser vaporisation) | P value |
|--|------------------|------------------------------|---|---------|
|  | N = 155          | N = 94 (60.6%)               | N = 61 (39.4%)                          |         |
| Maternal age at intervention, years                                    | 29 (26–32)       | 32 (28–34)                   | 31 (28–33)                              | 0.285   |
| Maternal age at delivery, years  | 31 (28–34)       | 29.5 (26–32)                 | 28 (26–31)                              | 0.275   |
| Interval between intervention and delivery, years                      | 2 (1–3)          | 2 (1–3)                      | 2 (1–3)                                 | 0.877   |
| Pregavid body mass index, kg/m <sup>2</sup>                            | 22.9 (20.3–26.5) | 23.2 (20.4–27.5)             | 22.5 (20.3–24.2)                        | 0.201   |
| Obesity (BMI ≥ 30 kg/m <sup>2</sup> )                                  | 20 (12.9%)       | 15 (16.0%)                   | 5 (8.2%)                                | 0.221   |
| Gravidity, n   | 2 (1–3)          | 2 (1–3)                      | 1 (1–2)                                 | 0.010   |
| Parity, n  | 1 (1–2)          | 2 (1–2)                      | 1 (1–2)                                 | 0.027   |
| Primiparous women, n   | 83 (53.5%)       | 44 (46.8%)                   | 39 (63.9%)                              | 0.048   |
| History of preterm birth or abortion > 16 weeks before intervention, n | 14 (9.0%)        | 9 (9.6%)                     | 5 (8.2%)                                | 1.000   |
| Nicotine abuse, n  | 18 (11.6%)       | 12 (12.8%)                   | 6 (9.84%)                               | 0.620   |
| Number of interventions, n   | 1 (1–1)          | 1 (1–1)                      | 1 (1–1)                                 | 0.483   |
| Assisted reproductive technique, n                                     | 7 (4.5%)         | 6 (6.4%)                     | 1 (1.6%)                                | 0.246   |
| HPV high risk  | 130 (90.9%)      | 78 (92.9)                    | 52 (88.1)                               | 0.384   |
| HSIL   | 134 (88.2%)      | 91 (96.8%)                   | 43 (74.1%)                              | < 0.001 |
| Gestational age at delivery, weeks                                     | 39 (38–40)       | 39 (38–40)                   | 39 (38–40)                              | 0.398   |
| Preterm birth < 37 weeks, n  | 15 (9.7%)        | 11 (11.7%)                   | 4 (6.7%)                                | 0.407   |
| Preterm birth < 34 weeks, n  | 4 (2.6%)         | 4 (4.3%)                     | 0 (0.0%)                                | 0.157   |
| Birth weight, g  | 3385 (3082–3730) | 3430 (3152–3767)             | 3380 (3020–3720)                        | 0.217   |
| Birth weight, percentile   | 60.5 (32–82.5)   | 63 (33–81)                   | 50 (24–83)                              | 0.206   |
| SGA, n   | 8 (5.2%)         | 4 (4.3%)                     | 4 (6.6%)                                | 0.713   |
| Caesarean sectio, n  | 42 (27.1)        | 25 (26.6%)                   | 17 (27.9%)                              | 0.856   |

► **Table 2** Patient characteristics comparing the groups with term birth and preterm birth.


|  | Term birth       | Preterm birth    | P value |
|--|------------------|------------------|---------|
|  | N = 140 (90.3%)  | N = 15 (9.7%)    |         |
| Maternal age at intervention, years                                    | 29 (26–32)       | 27 (24–29)       | 0.043   |
| Maternal age at delivery, years  | 31.5 (28–34)     | 29 (26–34)       | 0.108   |
| Interval between intervention and delivery, years                      | 2 (1–3)          | 2 (1–3)          | 0.459   |
| Pregravid body mass index, kg/m <sup>2</sup>                           | 22.9 (20.4–26.9) | 22 (20–25)       | 0.404   |
| Obesity (BMI ≥ 30 kg/m <sup>2</sup> )                                  | 20 (14.3%)       | 0 (0.0%)         | 0.220   |
| Gravidity, n   | 2 (1–3)          | 3 (1–5)          | 0.047   |
| Parity, n  | 1 (1–2)          | 1 (1–4)          | 0.176   |
| Primiparous women, n   | 75 (53.6%)       | 8 (53.3%)        | 1.000   |
| History of preterm birth or abortion > 16 weeks before intervention, n | 10 (7.1%)        | 4 (26.7%)        | 0.032   |
| Nicotine abuse, n  | 17 (12.1%)       | 1 (6.7%)         | 1.000   |
| LLETZ, n   | 83 (59.3%)       | 11 (73.3%)       | 0.407   |
| Number of interventions, n   | 1 (1–1)          | 1 (1–2.5)        | 0.001   |
| Repeated cervical intervention, n                                      | 22 (15.7%)       | 7 (46.7%)        | 0.011   |
| Cone depth, mm   | 10 (8–12)        | 10 (10–12.5)     | 0.278   |
| Cone depth ≥ 10 mm, n  | 42 (53.2%)       | 8 (80.0%)        | 0.176   |
| Cone diameter, mm  | 16.5 (13.5–20.0) | 17.8 (13.9–20.0) | 0.603   |
| Cone volume, cm <sup>3</sup>   | 1.9 (1.3–2.9)    | 2.5 (1.7–3.1)    | 0.302   |
| Cone volume > 3 cm <sup>3</sup> , n                                    | 80 (57.1%)       | 8 (53.3%)        | 0.790   |
| Assisted reproductive technique, n                                     | 5 (3.6%)         | 2 (13.3%)        | 0.138   |
| HPV high risk  | 119 (91.5%)      | 11 (84.6%)       | 0.335   |
| HSIL   | 120 (87.6%)      | 17 (93.3%)       | 1.000   |
| Gestational age at delivery, weeks                                     | 40 (39–40)       | 35 (32–36)       | <0.001  |
| 5'-APGAR   | 10 (9–10)        | 9 (9–10)         | 0.328   |
| Birth weight, g  | 3440 (3160–3813) | 2495 (1900–2640) | 0.217   |
| Birth weight, percentile   | 60.5 (32–81.5)   | 60.5 (28–78.25)  | 0.206   |
| SGA, n   | 8 (5.7%)         | 0 (0.0%)         | 1.000   |
| Caesarean section, n   | 36 (25.7%)       | 6 (60%)          | 0.237   |

### Pregnancy outcome and risk factors for preterm birth

PTB with delivery occurred in 9.7% (n = 15) below 37 weeks and in 2.6% (n = 4) below 34 weeks (► **Table 2**). Neither gestational age at delivery nor the frequency of PTB differed significantly between groups (► **Table 1**). In direct comparison, LLETZ revealed a non-significant trend to a higher proportion of PTB (11.7 vs. 6.7%, p = 0.407 for delivery < 37 weeks and 4.3% vs. 0%, p = 0.157 for delivery < 34 weeks).

The metric of the cone was available in 94.7% (89/95): 56.2% had a cone depth ≥ 10 mm and 22.5% ≥ 12 mm. A cone volume ≥ 3 cm<sup>3</sup> applied to 24.7% of patients. Neither median cone depth nor estimated cone volume differed between preterm and term birth groups (► **Table 2**, ► **Fig. 2**). Differences in women with and without preterm birth below 37 weeks' gestation are summarized in ► **Table 3** and ► **Fig. 3**. Repeated interventions were observed

in 46.7% (n = 7/15) of patients with PTB compared to 15.7% (n = 22/140, p = 0.009) with delivery at term. The proportion of PTB increased with the number of interventions: 6.3% with one, 13.6% with two and 57.1% with three interventions (p = 0.001). Risk of PTB was 24.1% if more than one intervention was performed. Interestingly, none of the patients with repeated LLETZ (n = 0/7) delivered preterm compared to six patients (n = 6/12, 50.0%) with LV after LLETZ and one patient (n = 1/10, 10%) with repeated LV. Additionally, a history of preterm birth or late miscarriage before cervical intervention was associated with an increased risk of PTB (OR 4.7 [95% CI 1.3–17.6], p = 0.020). Risk of PTB was also increased in younger women regarding the age at intervention as well as delivery (► **Table 3**).



► **Fig. 2** Cone depth and preterm birth. The boxplot diagram represents only women after LLETZ conisation with known cone depth ( $n = 89$ ) without difference between preterm birth ( $n = 10$ ) and term birth ( $n = 79$ ,  $p = 0.278$ ).

### Multiple Regression analysis with development of a combined risk model

For better prediction of PTB we developed a combined risk model by multiple regression analysis. The risk factors age at intervention and age at delivery were transformed in a binary variable after definition of the optimal cut-off by ROC-analysis. The first model included the following independent parameters: repeated intervention, history of PTB, age below 30 years at intervention, age below 28 years at delivery (► **Table 4**). The variable gravidity was dependent on history of PTB and BMI was neither predictive nor improved the model. Both parameters were excluded from the model.


In the second model the parameter of any repeated intervention was replaced by repeated intervention with LLETZ and LV (► **Table 4**). The ROC-AUC of the combined model 1 was 0.83 (95% CI 0.71–0.95,  $p < 0.001$ ). Model 2 performed marginally better with AUC 0.85 (95% CI 0.74–0.97,  $p < 0.001$ ). Subsequently, we developed a risk score. Scoring points were weighted by the regression coefficients of model 2: Repeated intervention with LV after LLETZ – 3 points, age at intervention  $< 30$  years – 2 points, age at delivery  $< 28$  years – 1 point, previous preterm birth – 1 point. The sum of the scoring point resulted in an AUC of 0.86 (95% CI 0.74–0.98,  $p < 0.001$ ) with an optimal cut-off value of four points (Fig. S1). The test characteristics of the combined score are presented in ► **Table 5**.

### Discussion

Numerous studies left no doubt as to the increased obstetrical risks of patients with a history of treated CIN. A recent meta-analysis of the Cochrane library with inclusion of 59 studies and more than five million participants indicated an increased risk for PTB below 37 weeks with a risk ratio (RR) of 1.75 (95% CI 1.57–1.96) [3]. However, several factors contribute to the risk estimation. On the one hand the risk depends on the chosen procedure and was higher in excisional compared to ablative treatments. The risk increases with the invasiveness of the surgical procedure and was lowest in the group of a cone depth below 10–12 mm (RR 1.54 [95% CI 1.09–2.18]). Risk estimation in dependence of the cone volume revealed similar results. Laser vaporization, a method of minimal invasiveness, was even not associated with an increase of risk (RR 1.04 [95% CI 0.86–1.26]) [3]. The findings of our study were comparable, even if the study size was insufficient for reaching the level of significance. With higher invasiveness of therapy, we found a trend to an increased proportion of PTB with a number needed to harm of 20 comparing LLETZ ± LV with LV alone. Depth and volume of the LLETZ specimens of our cohort belong mainly to the low risk category ( $< 12$  mm,  $< 3$  cm<sup>3</sup>).

► **Table 3** Risk factors of preterm birth.

| Risk factor                      | % with preterm birth in exposed group | % with preterm birth in non-exposed group | Unadjusted OR (95% CI) | P value   |
|----------------------------------|---------------------------------------|---|------------------------|-----------|
| Repeated LLETZ + LV              | 50.0%                                 | 6.3%                                      | 14.9 (4.0–55.6)        | $< 0.001$ |
| Age at intervention $< 30$ years | 15.1%                                 | 2.9%                                      | 6.0 (1.3–27.4)         | 0.022     |
| Age at delivery $< 28$ years     | 24.1%                                 | 6.3%                                      | 4.7 (1.5–14.3)         | 0.006     |
| Any repeated intervention        | 24.1%                                 | 6.3%                                      | 4.7 (1.5–14.3)         | 0.006     |
| History of PTB or late abortion  | 28.6%                                 | 7.8%                                      | 4.7 (1.3–17.6)         | 0.02      |
| ART                              | 28.6%                                 | 8.8%                                      | 4.2 (0.7–23.6)         | 0.108     |
| Cone depth $\geq 10$ mm          | 16.0%                                 | 5.1%                                      | 3.5 (0.7–17.7)         | 0.125     |
| HSIL                             | 10.4%                                 | 5.6%                                      | 2.0 (0.2–16.1)         | 0.521     |
| LLETZ                            | 73.3%                                 | 59.3%                                     | 1.9 (0.6–6.2)          | 0.296     |
| Nicotin abuse                    | 5.6%                                  | 10.2%                                     | 0.5 (0.06–4.2)         | 0.536     |



► **Fig. 3** Risk factors of preterm birth. The Forrest plot shows the crude odds ratios (squares) with 95% confidence intervals (whiskers). The dashed line marks the one on x-axis.

► **Table 4** Combined risk models of preterm birth with adjusted odds ratio and ROC-AUC.

| Risk factor                     | Model 1                   |                      |         | Model 2                   |                      |         |            |
|---------------------------------|---------------------------|----------------------|---------|---------------------------|----------------------|---------|------------|
|                                 | Coefficient of regression | Adjusted OR (95% CI) | P value | Coefficient of regression | Adjusted OR (95% CI) | P value | Risk score |
| Any repeated intervention       | 1.9                       | 6.5 (1.7–25.1)       | 0.006   |                           |                      |         |            |
| Repeated LLETZ + LV             |                           |                      |         | 3.1                       | 22.0 (3.8–129.0)     | 0.001   | 3          |
| Age at intervention <30 years   | 1.6                       | 4.9 (0.8–29.0)       | 0.078   | 1.9                       | 6.5 (0.9–47.9)       | 0.066   | 2          |
| Age at delivery <28 years       | 1.5                       | 4.3 (1.1–17.7)       | 0.041   | 1.2                       | 3.4 (0.8–14.5)       | 0.093   | 1          |
| History of PTB or late abortion | 1.5                       | 4.5 (0.9–22.5)       | 0.067   | 1.6                       | 4.9 (0.9–26.9)       | 0.065   | 1          |
|                                 |                           | ROC-AUC (95% CI)     |         |                           | ROC-AUC (95% CI)     |         |            |
|                                 |                           | 0.83 (0.71–0.95)     | <0.001  |                           | 0.85 (0.74–0.97)     | <0.001  |            |

► **Table 5** Test Characteristics of the risk score based on predictive model 2. A sum score ≥ 4 points was assumed as test positive.

|                      | Sensitivity | Specificity | PPV  | NPV  | pos. LR | neg. LR | Accuracy | OR (95% CI)     | P value |
|----------------------|-------------|-------------|------|------|---------|---------|----------|-----------------|---------|
| Sum score ≥ 4 points | 0.67        | 0.99        | 0.91 | 0.97 | 93      | 0.34    | 0.96     | 278 (29.6–2163) | <0.001  |

At least as important for the risk assessment is the choice of the comparison group [5]. Due to the lack of randomized controlled trials, it is necessary to choose an appropriate comparator. Lowest increase of risk for PTB was observed if women with dysplasia and without treatment were used as comparison group (RR 1.27 [95% CI 1.14–1.41]). However, this comparison group of the meta-analysis comprises a heterogeneous spectrum of patients, whose diagnosis was partly based on colposcopic findings alone. It suggests that the group contains a high proportion of transient HPV infection and low-grade dysplasia with spontaneous remission. In contrast to high-grade dysplasia, low-grade dysplasia was not associated with an increased risk of PTB [15]. A comparison with patients having an untreated high-grade squamous lesion (HSIL) seemed to be more suitable. In this subgroup analysis of the Cochrane meta-analysis, the cervical treatment did not result in an increased risk of PTB (RR 1.37 [95% CI 0.85–2.19])[3]. However, the analysis comprised only three studies with 742 untreated and 3022 treated participants [16, 17, 18]. A similar trend was observed, when the cohorts of the untreated HSIL patients were compared to the general healthy population (RR 1.4 [95% CI 0.94–2.1]). These data suggest an additional role of a persistent high-risk HPV infection for the increase of PTB risk. The results of a recent prospective study supported this hypothesis. In the Canadian HERITAGE study 899 pregnant women were tested on vaginal HPV DNA [19]. A persistent infection with the high-risk HPV types 16 and 18 during pregnancy was, independent of cervical treatment, associated with an increased risk of PTB (aOR 3.72 [95% CI 1.47–9.39]). Both HPV persistence and PTB share some risk factors like an inflammatory vaginal milieu due to bacterial vaginosis, aerobic vaginitis and cervicitis following infection with chlamydia trachomatis [10, 20, 21, 22, 23, 24, 25, 26]. Therefore, it remains unclear if the HPV infection is directly causal for the increased risk of PTB or if it is only an indicator for a high-risk milieu. In our study, a history of repeated cervical intervention obviously revealed a higher impact on risk of PTB as the type of intervention itself. It should be noticed that the risk of HPV infection as well as the development of a high-grade cervical dysplasia can be sufficiently reduced by vaccination. Vaccination after surgical intervention may also decrease the risk of a persistent HPV infection [27]. Interestingly, the increase of risk did not result from a higher invasiveness of the method of intervention, because LV in combination with LLETZ and not the repeated LLETZ gave rise to our observation. Patients with repeated intervention by LLETZ and LV had the greatest risk for PTB. Unfortunately, our data lack the information about the time interval between interventions. Nevertheless, we interpreted the results as follows: patients got a repeated LLETZ mainly because of residual disease after the first intervention whereas the combination of LLETZ and LV primary resulted from the persistence or recurrence of a HPV-associated dysplasia. Consequently, a persistence of high-risk HPV infection seemed to be associated with an increased risk of PTB. Younger age at intervention and delivery were further risk factors. In combination with a HPV induced dysplasia the younger age may indicate a susceptible subgroup of women with faster progression. It remains hypothetical if younger women with CIN represent a subgroup with a disturbed proinflammatory or immunodeficient milieu. Finally, a personal

history of PTB was a risk factor in our analysis, which should be independent from intervention indicating an increased basal risk.

For an optimal estimation of risk factors, the characteristics of the comparison group should be as similar as possible to the treatment group for minimizing the influence of possible confounders. Usually there is an indication for treatment in patients with persistent high-grade cervical dysplasia following a high-risk HPV infection. Using untreated patients as a comparator is hardly possible. As LV did not or did only marginally increase the risk of PTB, we used this mode of minimally invasive intervention as comparator. The resulting homogeneity of the study population's characteristics is a strength of our study, because it minimized the risk of a selection bias. However, the small size of our study population limited the power of our study. Some well-established risk factors did not reach the level of significance even the observed effect size was comparable to others [3]. Nevertheless, the study size was sufficient to verify the importance of repeated interventions as an independent risk factor for PTB. The developed risk score by combining the four significant risk factors demonstrated considerable test characteristics and could be helpful for simple risk estimation in the clinical situation. However, the predictive performance of the score needs to be proofed in the future.

## Conclusion

Although the exact connection between cervical dysplasia and preterm birth is unknown until today, a single treatment effect can be excluded. Within the present study, it was possible to confirm the impact of a repeated intervention on PTB risk, which was of greater relevance than the performance of a contemporary excisional treatment like LLETZ compared to ablative LV. We hypothesize that the persistence of a high-risk HPV infection gave rise to this observation.

## Author Contributions

- Johannes Stubert – manuscript writing, statistical analysis, development of the study concept.
- Elisa Stratmann – Data collection, statistical analysis, proof reading.
- Bernd Gerber – development of the study concept, proof reading.
- Ellen Mann – proof reading, development of the study concept.

## Funding Information

No specific funding from third parties was obtained.

## Key Message

Repeated cervical intervention revealed a greater impact on the risk of preterm birth than a single performance of a minimally invasive treatment method like large loop excision of the transformation zone (LLETZ) in comparison to ablative laser vaporization.



## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

- [1] Albrechtsen S, Rasmussen S, Thoresen S et al. Pregnancy outcome in women before and after cervical conisation: population based cohort study. *BMJ* 2008; 337: a1343. doi:10.1136/bmj.a1343
- [2] Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. *BJOG* 2011; 118: 1031–1041. doi:10.1111/j.1471-0528.2011.02944.x
- [3] Kyrgiou M, Athanasiou A, Kalliala IEJ et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane Database Syst Rev* 2017(11): CD012847. doi:10.1002/14651858.CD012847
- [4] Arbyn M, Kyrgiou M, Simoens C et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *BMJ* 2008; 337: a1284. doi:10.1136/bmj.a1284
- [5] Kyrgiou M, Athanasiou A, Paraskevasidi M et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. *BMJ* 2016; 354: i3633. doi:10.1136/bmj.i3633
- [6] Weinmann S, Naleway A, Swamy G et al. Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study. *PLoS One* 2017; 12: e0165276. doi:10.1371/journal.pone.0165276
- [7] Bruinsma F, Lumley J, Tan J et al. Precancerous changes in the cervix and risk of subsequent preterm birth. *BJOG* 2007; 114: 70–80. doi:10.1111/j.1471-0528.2006.01107.x
- [8] Simoens C, Goffin F, Simon P et al. Adverse obstetrical outcomes after treatment of precancerous cervical lesions: a Belgian multicentre study. *BJOG* 2012; 119: 1247–1255. doi:10.1111/j.1471-0528.2012.03429.x
- [9] Jar-Allah T, Karrberg C, Wiik J et al. Abnormal cervical cytology is associated with preterm delivery: A population based study. *Acta Obstet Gynecol Scand* 2019; 98: 777–786. doi:10.1111/aogs.13543
- [10] Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients—assessing their roles as human papillomavirus cofactors. *J Natl Cancer Inst Monogr* 2003(31): 29–34. doi:10.1093/oxfordjournals.jncimonographs.a003478
- [11] Khalid S, Dimitriou E, Conroy R et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. *BJOG* 2012; 119: 685–691. doi:10.1111/j.1471-0528.2011.03252.x
- [12] Voigt M, Rochow N, Hesse V et al. Short communication about percentile values of body measures of newborn babies. *Z Geburtshilfe Neonatol* 2010; 214: 24–29. doi:10.1055/s-0029-1241833
- [13] R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing;2020 . Accessed May 14, 2022 at: <http://www.R-project.org/>
- [14] RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, Inc.;2019 . Accessed May 14, 2022 at: <http://www.rstudio.com/>
- [15] Heinonen A, Gissler M, Paavonen J et al. Risk of preterm birth in women with cervical intraepithelial neoplasia grade one: a population-based cohort study. *Acta Obstet Gynecol Scand* 2018; 97: 135–141. doi:10.1111/aogs.13256
- [16] Ortoft G, Henriksen T, Hansen E et al. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. *BJOG* 2010; 117: 258–267. doi:10.1111/j.1471-0528.2009.02438.x
- [17] Shanbhag S, Clark H, Timmaraju V et al. Pregnancy outcome after treatment for cervical intraepithelial neoplasia. *Obstet Gynecol* 2009; 114: 727–735. doi:10.1097/AOG.0b013e3181b5cba3
- [18] El-Bastawissi AY, Becker TM, Daling JR. Effect of cervical carcinoma in situ and its management on pregnancy outcome. *Obstet Gynecol* 1999; 93: 207–212. doi:10.1016/s0029-7844(98)00386-x
- [19] Niyibizi J, Mayrand MH, Audibert F et al. Association Between Human Papillomavirus Infection Among Pregnant Women and Preterm Birth. *JAMA Netw Open* 2021; 4: e2125308. doi:10.1001/jamanetworkopen.2021.25308
- [20] Lasche M, Urban H, Gallwas J et al. HPV and Other Microbiota; Who's Good and Who's Bad: Effects of the Microbial Environment on the Development of Cervical Cancer—A Non-Systematic Review. *Cells* 2021; 10: 714. doi:10.3390/cells10030714
- [21] Kumari S, Bhor VM. Association of cervicovaginal dysbiosis mediated HPV infection with cervical intraepithelial neoplasia. *Microb Pathog* 2021; 152: 104780. doi:10.1016/j.micpath.2021.104780
- [22] Plisko O, Zodzika J, Jermakova I et al. Aerobic Vaginitis—Underestimated Risk Factor for Cervical Intraepithelial Neoplasia. *Diagnostics (Basel)* 2021; 11: 97. doi:10.3390/diagnostics11010097
- [23] Usyk M, Zolnik CP, Castle PE et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog* 2020; 16: e1008376. doi:10.1371/journal.ppat.1008376
- [24] Wang H, Ma Y, Li R et al. Associations of Cervicovaginal Lactobacilli With High-Risk Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia, and Cancer: A Systematic Review and Meta-Analysis. *J Infect Dis* 2019; 220: 1243–1254. doi:10.1093/infdis/jiz325
- [25] Donders GG, Van Calsteren K, Bellen G et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. *BJOG* 2009; 116: 1315–1324. doi:10.1111/j.1471-0528.2009.02237.x
- [26] Goldenberg RL, Culhane JF, Iams JD et al. Epidemiology and causes of preterm birth. *Lancet* 2008; 371: 75–84. doi:10.1016/S0140-6736(08)60074-4
- [27] Hillemanns P, Friese K, Dannecker C et al. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/0270L, December 2017) – Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia. *Geburtshilfe Frauenheilkd* 2019; 79: 148–159. doi:10.1055/a-0818-5440